Please login to the form below

Not currently logged in
Email:
Password:

Abilify Maintena

This page shows the latest Abilify Maintena news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this ... injectable in 14 European

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics